




RealRate

PHARMACEUTICAL 2015

Ocata Therapeutics Inc
Rank 265 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Ocata Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ocata Therapeutics Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1.1% points. The greatest weakness of Ocata Therapeutics Inc is the variable Assets, reducing the Economic Capital Ratio by 128% points.

The company's Economic Capital Ratio, given in the ranking table, is 10%, being 244% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	4,749
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,676
Liabilities, Non-Current	0
Other Assets	155
Other Compr. Net Income	0
Other Expenses	13,469
Other Liabilities	2,797
Other Net Income	301
Other Revenues	0
Property and Equipment	833
Research and Development	10,529
Selling, General and Administrative Expense	11,052

Output Variable	Value in 1000 USD
Assets	5,737
Liabilities	8,473
Expenses	35,050
Revenues	0
Stockholders Equity	-2,736
Net Income	-34,749
Comprehensive Net Income	-34,749
BaseVar	24,781
ECR before LimitedLiability	-573%
Economic Capital Ratio	10%